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Background: The minerals, vitamins, soluble dietary fibers, and flavonoids of seaweed are 2 
protective for prevent cardiovascular diseases. However, the association between seaweed 3 
intake and risk of cardiovascular disease has not been established. 4 
Objectives: We examined the dietary intake of seaweed and its impact upon stroke and 5 
ischemic heart disease risk among a Japanese study population. 6 
Design: We surveyed 40,707 men and 45,406 women from 2 large cohorts (age range: 40–69 7 
years). Seaweed intake was determined by food frequency questionnaire at baseline (1990–8 
1994). Incidences of stroke and ischemic heart disease were ascertained until the end of 2009 9 
(Cohort I) or 2012 (Cohort II). Sex-specific cardiovascular disease hazard ratios (95% 10 
confidence intervals) were estimated using Cox proportional hazard models after 11 
stratification by area and adjustment for cardiovascular risk and dietary factors.  12 
Results: During 1,493,232 person-years of follow-up, 4,777 strokes (2,863 ischemic stroke, 13 
1361 intraparenchymal hemorrhages and 531 subarachnoid hemorrhages) and 1,204 ischemic 14 
heart disease cases were identified. Among men, the multivariable hazard ratios for almost 15 
daily consumption versus almost no consumption of seaweed were only seen in ischemic 16 
heart disease: 0.76 (0.58, 0.99; P for trend = 0.04) and total cardiovascular diseases: 0.88 17 
(0.78, 1.00; P for trend = 0.08). Among women, such inverse associations were 0.56 (0.36, 18 
0.85; P for trend = 0.01) for ischemic heart disease, and 0.89 (0.76, 1.05; P for trend = 0.10) 19 
for total cardiovascular diseases. No significant associations were observed between seaweed 20 
intake and risk of total stroke or stroke types among either men or women. 21 
Conclusions: Seaweed intake was inversely associated with risk of ischemic heart disease. 22 




Seaweed, outside of industrial food processing, is not widely eaten in the West but is broadly 25 
consumed in East Asian countries. It contains healthy components such as high levels of 26 
potassium, carotenoid, and dietary fiber (1, 2), and the most commonly used seaweeds in 27 
food preparation include the following species: brown seaweeds (Undalia pinnatifida 28 
[Wakame in Japanese], kelp (Laminaria [Konbu], Hizikia fusiformis [Hijiki]), red seaweeds 29 
and green seaweeds (Laver [Nori]). Although seaweed consumption is not a traditional part of 30 
the Western diet, the globalization of cuisine and an increased proportion of Asian 31 
immigrants may work to increase future consumption in Western countries. 32 
Previous studies showed that seaweed components, such as carotenoids, peptides, and 33 
fiber were related to lower levels of serum total cholesterol, blood pressure, body weight and 34 
blood glucose in both animals (3–8) and humans (9–14). As the Japan Public Health Center-35 
based Prospective (JPHC) Study showed that dietary fiber was associated inversely with risk 36 
of cardiovascular disease (15), seaweed intake may be prophylactic in this regard.  37 
However, an association between seaweed intake and the incidence of cardiovascular 38 
disease has not been established. The aim of the present study was therefore to determine any 39 
associations between dietary intake of seaweed and risks of total stroke, stroke types 40 
(ischemic stroke, intraparenchymal hemorrhage and subarachnoid hemorrhage), ischemic 41 
heart disease (myocardial infarction and sudden cardiac death) and total cardiovascular 42 
diseases among Japanese men and women. As the Japanese are a unique population which 43 
consumes extremely high amounts of seaweeds compared to the rest of the world (2), any 44 
beneficial impact of seaweed may be more easily detected.  45 
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SUBJECTS AND METHODS 46 
Study population 47 
The JPHC study consists of two subcohorts based on public health center (PHC) areas; 48 
Cohort I (started in 1990, five PHC areas, participants aged 40–59 years) and Cohort II 49 
(started in 1993, six PHC areas, participants aged 40–69 years). The study design has been 50 
described in detail previously (16). The JPHC study was approved by the institutional review 51 
boards of the National Cancer Center, Osaka University and the University of Tsukuba. 52 
The JPHC Study is an ongoing cohort study comprising a community-based sample of 53 
140,420 Japanese participants (68,722 men and 71,698 women) that follows up on incidences 54 
of cancer and cardiovascular diseases. However, participants in two PHC areas (Tokyo and 55 
Osaka) were excluded from the present study because the incidence of cardiovascular disease 56 
was unable to be followed up in these two communities, leaving 116,896 remaining 57 
participants as eligible for the follow-up study. Participants were asked to complete self-58 
administered questionnaires about their lifestyles and medical histories. Informed consent 59 
was obtained before questionnaire completion or was sometimes obtained from community 60 
leaders instead of individuals as this was common practice for informed consent in Japan at 61 
that time. 62 
Baseline questionnaire 63 
A self-administered questionnaire included demographic characteristics, medical history, 64 
physical activity level, smoking, drinking, and dietary habits. This questionnaire, including a 65 
food frequency questionnaire (FFQ), was distributed to all eligible study participants in 1990 66 
for Cohort I and in 1993–94 for Cohort II. The FFQ included 44 food items for Cohort I and 67 
52 food items for Cohort II. Both cohort FFQs included an item about typical seaweed intake 68 
and contained four or five frequency categories for seaweeds (Wakame, Konbu, Nori and 69 
more), ranging from “almost never,” “1–2 days/week,” “3–4 days/week” to “almost daily,” in 70 
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Cohort I and from “rarely,” “occasionally,” “1–2 days/week,” “3–4 days/week” to “almost 71 
daily,” in Cohort II. For analysis, we combined the data from both cohorts, classifying the 72 
participants into four groups according to their frequencies of seaweed intake: “almost no 73 
consumption (almost never, rarely or occasionally)”, “1–2 days/week”, “3–4 days /week”, 74 
and “almost daily consumption.” Validation of the FFQ was done by comparing the 75 
frequency of seaweed intake from FFQ to that from dietary records over seven consecutive 76 
days in each of four seasons (Spring, Summer, Fall and Winter). The Spearman’s correlation 77 
coefficients between the frequency of seaweed intake based on the FFQ and dietary records 78 
among subsamples of 122 men and 125 women in Cohort I and 176 men and 178 women in 79 
Cohort II were moderate: 0.37 and 0.33, respectively, in Cohort I (17) and 0.27 and 0.40, 80 
respectively, in Cohort II (unpublished data). 81 
Stroke and ischemic heart disease registry 82 
The nine PHC areas were comprised of 78 total hospitals, which were core hospitals capable 83 
of treating cardiovascular disease events. Physicians in the hospitals, PHCs, or research 84 
physician-epidemiologists (all blinded to patient lifestyle data) reviewed the medical records 85 
of cohort participants at each hospital and extracted clinical information, including brain 86 
images, electrocardiographs, and enzyme test results, onto cohort-specific registration forms. 87 
To confirm the fatal cardiovascular disease events, we used the information on death 88 
certificates. All death certificates were forwarded to the PHC in the area of residency, and the 89 
mortality data was sent to the Ministry of Health, Welfare and Labor to be coded for national 90 
vital statistics. As registration of deaths is required by the Family Registration Law in Japan, 91 
we were assured that all relevant causes of deaths were recorded. 92 
Stroke was confirmed according to the criteria of the National Survey of Stroke (18), 93 
which requires the presence of focal neurological deficits of sudden or rapid onset lasting at 94 
least 24 hours or until death. Stroke was classified into ischemic strokes, intraparenchymal 95 
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hemorrhages, and subarachnoid hemorrhages. As participating hospitals were equipped with 96 
computed tomography and/or magnetic resonance imaging scans, imaging was available for 97 
97% of registered stroke events.  98 
Ischemic heart disease was defined as myocardial infarction and sudden cardiac death. 99 
Myocardial infarction was confirmed in the medical records according to the criteria of the 100 
Monitoring Trends and Determinants of Cardiovascular Disease (MONICA) project (19), 101 
which requires typical chest pain and evidence from electrocardiography and/or cardiac 102 
enzyme levels. For those cases with typical prolonged chest pain (≥20 min) but not confirmed 103 
by electrocardiography or cardiac enzyme tests, a tentative myocardial infarction diagnosis 104 
was made and these were included in myocardial infarction cases. Deaths within 28 days of 105 
the onset of myocardial infarction and sudden cardiac deaths were regarded as fatal coronary 106 
events while sudden cardiac death was defined as a death of unknown origin that occurred 107 
within 1 hour of the event onset. The primary outcome of this study is incident cardiovascular 108 
diseases (total stroke, stroke types and ischemic heart disease) and both fatal and nonfatal 109 
cases were included. 110 
Total cardiovascular disease was defined as total stroke, stroke types and ischemic heart 111 
disease, whichever occurred first, during the follow-up. 112 
Statistical analysis 113 
Follow-ups were started from the completion of the questionnaire and ended on the dates of 114 
death, emigration, incident stroke/ischemic heart disease events, or the end of either 2009 (for 115 
Cohort I) or 2012 (for Cohort II), whichever came first.  116 
Within the pool of 116,896 participants, we excluded those who were lost to, or refused 117 
follow-up (n=240), leaving a total of 116,656 people from the two cohorts (Cohorts I and II) 118 
who were eligible for participation in the present study. Of these, 94,275 participants (81%) 119 
completed the baseline questionnaires, including information on seaweed intake. In addition, 120 
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we excluded persons who had histories of stroke, angina pectoris, myocardial infarction or 121 
cancer at the time of the baseline questionnaires (n=3,630). We further excluded persons with 122 
a total energy intake of less than 2.5 or more than the 97.5 percentile (n=4,532). Ultimately, 123 
86,113 people (40,707 men and 45,406 women) were included in the present study. 124 
Sex-specific, age-adjusted mean values and prevalence of selected factors were 125 
calculated and compared among the frequencies of seaweed intake using linear or logistic 126 
regression analyses. The person-years of follow-up for each participant were calculated from 127 
the baseline to the first endpoint which was defined as a cardiovascular event, a death, a 128 
move from the community, or the end of the follow-up period (2009 for Cohort I and 2012 129 
for Cohort II).  130 
Sex-specific, area (nine PHCs) -stratified and age (continuous) -adjusted hazard ratios 131 
(HRs) and 95% confidence intervals (CIs) were calculated using Cox proportional hazard 132 
models. We confirmed the proportional hazards assumption according to the frequency of 133 
seaweed intake by time interactions, and found that the assumption was not violated. For 134 
seaweed intake categories, dummy variables were created, and the almost no consumption 135 
group was regarded as the reference. We further adjusted for body mass index (quintile), 136 
histories of hypertension and diabetes mellitus, including treatment (yes or no), treatment for 137 
hypercholesterolemia (yes or no), leisure-time physical activity (no, 1–3 days/month, 1–2 138 
days/week, 3–4 days/week and almost every day), smoking status (never, ex-smoker and 139 
current smoker), alcohol intake (0, 1–149, 150–299, 300–449 and 450 g/week or more), 140 
quartiles of total energy intake, dietary intakes of vegetables, fruits, red meat, processed meat, 141 
fish, soy, green tea and sodium. The food intakes were estimated by the Japan Food Table, 5th 142 
version. Trend tests were performed by allocating scores of 0, 1.5, 3.5 and 6 for each seaweed 143 
intake groups. 144 
The socio-economic status may be an important confounding factor, but we did not have 145 
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information except for education levels in subcohort (Cohort I). Therefore, we additionally 146 
performed subgroup analyses in Cohort I adjusting for education levels (junior high school or 147 
less, high school, and university or higher education). 148 
We used SAS version 9.4 software (SAS Institute Inc, Cary, NC) for the analyses. All 149 
probability values for statistical tests were two-tailed, and values where p<0.05 were regarded 150 
as statistically significant.  151 
 152 




The baseline survey revealed that those respondents who consumed seaweeds frequently 155 
tended to consume more energy-adjusted dietary intakes of vegetables, fruits, red and 156 
processed meat, fish, soy and sodium, and as well as have lower proportions of current 157 
smokers among both men and women. 158 
During 1,493,232 person-years of follow-up in 86,113 men and women, 5,873 (3,611 in 159 
men and 2,262 in women) incident cases of total cardiovascular disease, including 2,863 160 
(1,805 in men and 1,058 in women) ischemic strokes, 1,361 (805 in men and 556 in women) 161 
intraparenchymal hemorrhages, 531 (180 in men and 351 in women) subarachnoid 162 
hemorrhages, 1,204 (884 in men and 320 in women) ischemic heart disease events were 163 
identified. Total seaweed intake by the participants ranged from a mean value of 0.3 g/day in 164 
the almost no consumption to 4.7 g/day in the almost daily consumption groups among men 165 
and 0.2 g/day to 3.9 g/day, respectively, among women (Table 1). 166 
Seaweed intake was inversely associated with risk of ischemic heart disease among men 167 
and women. The multivariable HRs (95%CIs) for the almost daily consumption versus the 168 
almost no consumption groups were 0.76 (0.58, 0.99; P for trend=0.04) for ischemic heart 169 
disease and 0.88 (0.78, 1.00; P for trend=0.08) for total cardiovascular disease among men 170 
(Table 2). The multivariable HRs (95% CIs) among women were 0.56 (0.36, 0.85; P for 171 
trend=0.01) for ischemic heart disease and 0.89 (0.76, 1.05; P for trend=0.10) for total 172 
cardiovascular diseases (Table 3). 173 
To examine any potential reverse causation for the frequency of seaweed intake and risk 174 
of cardiovascular disease, we performed the same analyses but excluded early events (≤5 years 175 
from the baseline). These associations did not materially alter any outcomes among either men 176 
or women (data not shown). When we further adjusted for education levels in this subgroup 177 
(Cohort I, n=39,176), these associations were not materially altered for any outcomes among 178 
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either men or women (data not shown). 179 




In this large, prospective study of middle-aged Japanese men and women, we found an 182 
inverse association between seaweed intake and risk of ischemic heart disease that was more 183 
pronounced among women. To our knowledge, this is the first study to show an association 184 
between seaweed intake and risk of incident cardiovascular disease. Another previous 185 
Japanese cohort study showed a significant inverse association between the frequency of 186 
seaweed intake and age-adjusted mortality from stroke (not ischemic heart disease) among 187 
women, but not among men (20). In that study, however, the adjustment for potential 188 
confounding factors was not conducted and the risk of cardiovascular disease mortality, 189 
instead of incidence, was examined. 190 
One possible mechanism for the protective effect of seaweed against the risk of ischemic 191 
cardiovascular disease is a lipid-lowering effect as shown in a previous study of 192 
apolipoprotein E-deficient mice where fucoidan contained in seaweed regulated the 193 
metabolism of serum lipids by increasing lipoprotein lipase activity (21), reducing blood 194 
levels of triglycerides and low-density lipoprotein cholesterol. Furthermore, the 195 
supplementation of a high-fat diet with 5% fucoidan for 12 weeks attenuated the development 196 
of atherosclerosis and plaque formation compared to a high-fat diet alone (21). Another 197 
possible mechanism is a blood pressure lowering effect. Peptides isolated from wakame have 198 
inhibitory activity for the angiotensin-1-converting enzyme, leading to decreases in blood 199 
pressure in spontaneously hypertensive rats (6). In humans, a randomized controlled trial 200 
showed that diastolic blood pressure levels in hypertensive patients decreased by 8 mmHg 201 
after treatment with 5 g/day wakame powder for 8 weeks, whereas the decrease in the non-202 
treated group was not significant (9). In addition, a double-blinded crossover trial using a 4-203 
week supplement of 12 or 24g/day, but not 6g/day seaweed fiber showed that untreated mild 204 
hypertensive patients saw a significant decrease in mean blood pressure compared with the 205 
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placebo group (11). Accordingly, another study in a spontaneously hypertensive rat model 206 
using 1% NaCl supplementation in drinking water showed a 4-fold increase in fecal sodium 207 
excretion in the intervention group fed on 10% alginic acid (the main soluble fiber of 208 
seaweed) compared with a control group fed on 10% kaolin (22). Ikeda et al. (4) reported that 209 
blood pressure levels in stroke-prone spontaneously hypertensive rats given 0.5% NaCl-210 
supplemented drinking water and wakame powder did not differ with groups given cellulose 211 
or kaolin control supplements. However, the mean life-span of the wakame powder group 212 
was significantly extended compared to controls (77 days for wakame group vs. 62 days for 213 
the control group). In that study, neuronal cell injury after 4-day hypoxic insult was 214 
attenuated in a dose-dependent fashion by the addition of 152 or 1520 nmol/L fucoxanthin 215 
isolated from seaweeds, suggesting that wakame may have a beneficial effect on stroke 216 
independent of blood pressure-lowering effect (4). In the present study, the adjustment for 217 
history of hypertension and treatment of hypercholesterolemia did not alter the results. These 218 
variables, however, were not minute so that the residual confounding may remain. 219 
Seaweed intake may be a marker of healthy dietary patterns. A previous principal 220 
component analysis run in the JPHC Study identified that seaweed intake consisted of a 221 
‘prudent’ (healthy) dietary pattern that involved vegetables, fruit, potatoes, soy products, 222 
mushrooms, seaweed, fish, and green tea (23). Among these foods, potatoes and mushrooms 223 
were not adjusted in our analysis, because these intakes were not confounded for the 224 
association with the risk of ischemic heart disease in our cohort (data not shown). 225 
Furthermore, when we adjusted for modified DASH dietary score (including vegetables, 226 
fruits, red and processed meat intake, dairy instead of low-fat dairy, soy instead of nuts and 227 
legumes, sodium, and sweetened beverages), the results did not change materially (data not 228 
shown). Therefore, these results support that seaweed may lower the risk of cardiovascular 229 
disease independent of healthy dietary pattern. 230 
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Some kinds of seaweed, particularly Hizikia fusiformis (Hijiki), are rich in inorganic 231 
arsenic, which has been suggested to be associated with increased risk of cardiovascular 232 
disease (24). Potential mechanisms for arsenic-related atherosclerosis include endothelial 233 
dysfunction, smooth-muscle proliferation, and enhanced platelet aggregation (25). However, 234 
we did not find any adverse effect of seaweed on cardiovascular diseases suggesting that 235 
adverse impact of arsenic, if any, may be overwhelmed by the beneficial effect of seaweed as 236 
discussed above. Furthermore, inorganic arsenic in Hijiki could be removed by soaking in 237 
water and boiling when cooking (26, 27). 238 
The strengths of the present study included its large sample size, a population-based 239 
prospective design, a high follow-up rate, the use of validated FFQ and cardiovascular 240 
incident data, and the extensive adjustment for potentially important confounding factors, 241 
including physical activity level, smoking status, alcohol intake, and other food items. 242 
Japanese are a unique population who consume an extremely high amount of seaweeds, 243 
which allowed us to perform associative studies of a large distribution of seaweed intake with 244 
incident cardiovascular disease. As seaweed in non-Asian countries is mostly used in 245 
industrial food processing, this type of study could not be performed in Western populations. 246 
Several limitations in the present study warrant discussion. First, although validated by 247 
dietary records, the use of an FFQ inevitably leads to seaweed intake misclassification. The 248 
low correlation coefficients between the frequency of seaweed intake (based on FFQ) and 249 
dietary records suggest that the self-reported intake is subject to measurement errors. 250 
However, as any misclassification was likely to be random concerning the outcome, this was 251 
not thought to impact the results greatly. Second, we could not negate the possibility of 252 
residual confounding by unmeasured variables such as socio-economic status. When we 253 
further adjusted for education levels (junior high school or less, high school, and university or 254 
higher education) in the subgroup, there were no substantial changes in the results for either 255 
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men or women (not shown in Table). 256 
In conclusion, seaweed intake was significantly and inversely associated with risk of 257 
ischemic heart disease. Our results suggest that a high seaweed intake may have a beneficial 258 
effect on cardiovascular disease among middle-aged men and women.  259 
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Table 1. Baseline cardiovascular risk factors and selected dietary variables among 40,707 men and 45,406 women according to the  
 
frequency of seaweed intake1 
 Men Women    
                     
 Frequency of seaweed intake 
 
  












Almost daily P for 
consumption consumption difference consumption consumption difference 
          
Number at risk 9,033 14,067 11,826 5,781  6,537 13,351 16,197 9,321  
           
Age at baseline, 
mean 52.7±8.7 51.0±7.7 51.7±7.7 52.6±7.6 0.07 54.2±8.9 51.3±7.9 51.9±7.6 52.4±7.5 <0.001 
           
Body mass index, 
kg/m2 23.5±3.0 23.5±2.9 23.5±2.8 23.4±2.9 0.002 23.6±3.4 23.5±3.1 23.5±3.2 23.5±3.1 0.009 
           
Treatment for 
hypertension, % 18.1±39.2 18.3±38.0 18.5±38.8 19.2±40.0 0.02 17.8±40.2 17.6±37.2 17.4±37.6 17.8±38.6 0.24 




1.0±10.3 1.1±10.3 1.6±12.4 1.6±12.6 <0.001 1.1±12.0 2.0±13.4 2.2±14.7 2.3±15.3 <0.001 




6.4±24.8 5.9±23.1 6.4±24.5 6.9±25.8 0.05 3.3±18.8 3.0±16.6 2.9±16.7 2.8±16.7 0.29 
           
Current 
smokers, % 56.7±49.6 52.0±50.0 51.1±50.0 48.9±50.0 <0.001 8.0±26.6 6.0±30.3 4.8±21.6 4.1±19.8 <0.001 
           
Alcohol intake 
≥450 ml/week, % 24.8±43.1 21.6±41.1 22.2±41.6 22.0±41.7 0.002 4.8±21.5 3.5±18.4 2.7±16.1 3.3±17.7 0.04 
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Leisure-time 
physical activity ≥ 
3 times/week, % 
8.2±27.9 9.1±28.4 10.1±30.1 11.6±32.4 <0.001 7.8±27.9 7.0±24.9 8.8±28.2 11.2±31.7 <0.001 
           
Dietary intake2           
           
  Total energy 
intake, kcal/day 1,662±479 1,852±499 1,992±500 2,080±502 <0.001 1,072±250 1,213±306 1,326±328 1,425±359 <0.001 
           
  Vegetable 
intake, g/day 58±41 100±47 128±48 158±60 <0.001 73±52 102±60 126±63 154±76 <0.001 
           
  Fruit intake, 
g/day 51±64 68±72 81±82 94±103 <0.001 84±67 97±80 109±85 122±104 <0.001            
  Red meat 
intake, g/day 16.5±11.7 21.1±13.8 24.4±16.2 25.2±18.7 <0.001 14.9±9.4 17.0±11.5 18.5±13.2 19.2±16.0 <0.001 
           
  Processed meat 
intake, g/day 2.6±3.1 3.5±3.7 4.1±4.2 4.3±5.0 <0.001 2.9±3.0 3.3±3.5 3.6±3.9 3.8±4.7 <0.001 
           
  Fish intake, 
g/day 50±36 51±33 59±35 67±41 <0.001 39±27 42±26 48±28 54±32 <0.001 
           
  Soy intake, 
g/day 42±26 48±25 58±25 68±25 <0.001 42±25 47±23 54±23 62±23 <0.001 
           
  Green tea 
intake, ml/day 446±360 406±334 411±331 419±332 <0.001 431±328 398±312 409±310 403±306 0.07 
           
  Seaweed intake, 
g/day 0.3±0.1 1.1±0.2 2.4±0.5 4.7±1.1 <0.001 0.2±0.1 0.9±0.2 2.0±0.5 3.9±0.9 <0.001 
           
  Sodium intake,  
g/day 4.1±1.7 4.8±2.0 5.3±2.1 5.7±2.2 <0.001 3.8±1.4 4.2±1.8 4.5±1.9 4.7±2.0 <0.001 
1Sex-specific, age-adjusted mean (unadjusted standard deviations), or age-adjusted percentages were calculated according to the frequency of            





2Energy-adjusted values except for total energy intake.                 
*P-values for the overall difference using analysis of covariance.     
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Table 2. Multivariable-adjusted HRs and 95% confidence intervals for risk of incident total cardiovascular diseases, total stroke,        
stroke types and ischemic heart disease according to the frequency of seaweed intake among 40,707 men1 
           
    Frequency of seaweed intake   
            
  Almost no 
consumption 1-2 days/week 3-4 days/week 
Almost daily 
consumption P for trend 
       
Number of men at risk 9,033 14,067 11,826 5,781  
       
Person years 144,764 237,476 199,746 96,497          
Total stroke, n 646 916 813 429         
 Model 1  1.00 0.87 (0.78, 0.97) 0.85 (0.76, 0.95) 0.88 (0.77, 0.998) 0.08 
       
 Model 2 1.00 0.93 (0.83, 1.04) 0.91 (0.81, 1.03) 0.93 (0.80, 1.07) 0.35 
       
Ischemic stroke, n 434 571 526 274         
 Model 1 1.00 0.83 (0.73, 0.95) 0.83 (0.73, 0.96) 0.84 (0.71, 0.98) 0.08 
       
 Model 2 1.00 0.89 (0.77, 1.02) 0.91 (0.78, 1.05) 0.91 (0.76, 1.09) 0.53        
Intraparenchymal hemorrhage, n 173 274 238 120         
 Model 1 1.00 0.95 (0.78, 1.17) 0.93 (0.75, 1.15) 0.94 (0.73, 1.20) 0.59 
       
 Model 2 1.00 1.03 (0.83, 1.27) 0.98 (0.78, 1.24) 0.94 (0.71, 1.24) 0.52 
       
Subarachnoid hemorrhage, n 37 65 44 34         
 Model 1 1.00 0.89 (0.58, 1.39) 0.66 (0.41, 1.08) 1.04 (0.62, 1.75) 0.90        
 Model 2 1.00 0.94 (0.59, 1.50) 0.67 (0.40, 1.14) 1.01 (0.56, 1.79) 0.80        
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Ischemic heart disease, n 220 303 246 115  
       
 Model 1 1.00 0.83 (0.69, 0.997) 0.77 (0.63, 0.94) 0.72 (0.57, 0.91) 0.007 
       
 Model 2 1.00 0.87 (0.70, 1.03) 0.79 (0.64, 0.98) 0.76 (0.58, 0.99) 0.04 
       
Total cardiovascular diseases, n 846 1192 1038 535         
 Model 1 1.00 0.86 (0.78, 0.95) 0.83 (0.76, 0.92) 0.84 (0.75, 0.95) 0.006 
       
 Model 2 1.00 0.91 (0.82, 1.00) 0.88 (0.79, 0.98) 0.88 (0.78, 1.00) 0.08        
1HRs (95% CIs) were derived from Cox proportional hazards regression models. Model 1 was stratified by area and adjusted for age. 
 
Model 2 was adjusted further for body mass index, leisure-time physical activity, smoking status, alcohol intake, histories of  
 
hypertension or diabetes mellitus, treatment for hypercholesterolemia, total energy intake, dietary intakes of vegetables, fruits,  
 






Table 3. Multivariable-adjusted HRs and 95% confidence intervals for risk of incident total cardiovascular diseases, total         
stroke, stroke types and ischemic heart disease according to the frequency of seaweed intake among 45,406 women1 
             
  Frequency of seaweed intake  
            
   Almost no consumption 1-2 days/week 3-4 days/week 
Almost daily 
consumption P for trend 
       
Number of women at risk 6,537 13,351 16,197 9,321  
         
Person years 113,514 239,797 292,681 168,757   
             
Total stroke, n 309 567 680 417  
        
  Model 1 1.00 0.96 (0.83, 1.11) 0.88 (0.76, 1.01) 0.88 (0.75, 1.03) 0.05 
        
  Model 2 1.00 1.05 (0.90, 1.22) 0.98 (0.84, 1.15) 0.96 (0.81, 1.15) 0.36 
        
Ischemic stroke, n 186 314 348 210  
        
  Model 1 1.00 0.96 (0.79, 1.15) 0.80 (0.66, 0.97) 0.78 (0.63, 0.97) 0.004 
        
  Model 2 1.00 1.05 (0.86, 1.28) 0.93 (0.76, 1.15) 0.90 (0.71, 1.14) 0.16 
        
Intraparenchymal hemorrhage, n 73 150 207 126  
        
  Model 1 1.00 1.06 (0.79, 1.42) 1.14 (0.85, 1.51) 1.14 (0.84, 1.55) 0.35 
        
  Model 2 1.00 1.16 (0.86, 1.57) 1.29 (0.95, 1.75) 1.25 (0.89, 1.76) 0.23 
      
Subarachnoid hemorrhage, n 48 102 124 77  
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  Model 1 1.00 0.91 (0.63, 1.30) 0.83 (0.58, 1.18) 0.84 (0.57, 1.24) 0.37 
        
  Model 2 1.00 0.94 (0.64, 1.37) 0.81 (0.55, 1.20) 0.78 (0.51, 1.20) 0.18 
        
Ischemic heart disease, n 74 89 109 48  
        
  Model 1 1.00 0.72 (0.53, 0.996) 0.71 (0.52, 0.97) 0.52 (0.36, 0.77) 0.002 
        
  Model 2 1.00 0.75 (0.54, 1.05) 0.74 (0.52, 1.04) 0.56 (0.36, 0.85) 0.01 
        
  
Total cardiovascular diseases, n 376 647 779 460  
        
  Model 1 1.00 0.92 (0.81, 1.05) 0.85 (0.74, 0.97) 0.82 (0.71, 0.95) 0.004 
        
  Model 2  1.00 0.99 (0.86, 1.14) 0.94 (0.82, 1.09) 0.89 (0.76, 1.05) 0.10 
        
1HRs (95% CIs) were derived from Cox proportional hazards regression models. Model 1 was stratified by area and adjusted for age. 
 
Model 2 was adjusted further for body mass index, leisure-time physical activity, smoking status, alcohol intake, histories of  
 
hypertension or diabetes mellitus, treatment for hypercholesterolemia, total energy intake, dietary intakes of vegetables, fruits, 
 
red meat, processed meat, fish, soy, green tea and salt. 
 
